Alalevonadifloxacin

Alalevonadifloxacin
Clinical data
Trade names	Emrok O
Routes of; administration	Oral
Legal status
Legal status	Rx in India;
Identifiers
	IUPAC name (12S)-8-[4-[(2S)-2-Aminopropanoyl]oxypiperidin-1-yl]-7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid;
CAS Number	706809-20-3;
PubChem CID	16734914;
IUPHAR/BPS	10756;
ChemSpider	19538972;
UNII	57B7E1D1TG;
ChEMBL	ChEMBL5095635;
Chemical and physical data
Formula	C22H26FN3O5
Molar mass	431.464 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)OC(=O)[C@H](C)N)F)C(=O)O;
	InChI InChI=InChI=1S/C22H26FN3O5/c1-11-3-4-14-18-15(20(27)16(21(28)29)10-26(11)18)9-17(23)19(14)25-7-5-13(6-8-25)31-22(30)12(2)24/h9-13H,3-8,24H2,1-2H3,(H,28,29)/t11-,12-/m0/s1; Key:OUXXDXXQNWKOIF-RYUDHWBXSA-N;

Alalevonadifloxacin (trade name Emrok O) is an antibiotic of the fluoroquinolone class.^[1] It is a prodrug of levonadifloxacin with increased oral bioavailability.^[2] In India, it is approved for the treatment of infections with Gram-positive bacteria.^[3]

References[edit]

^ Saseedharan S, Dubey D, Singh RK, Zirpe K, Choudhuri AH, Mukherjee DN, et al. (2024). "Treatment challenges in the management of difficult-to-treat gram-positive infections: A consensus view apropos therapeutic role of novel anti-MRSA antibiotics, levonadifloxacin (IV) and alalevonadifloxacin (oral)". Indian Journal of Medical Microbiology. 47: 100528. doi:10.1016/j.ijmmb.2024.100528. PMID 38228227.
^ Bhawsar S, Kale R, Deshpande P, Yeole R, Bhagwat S, Patel M (December 2021). "Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection". Bioorganic & Medicinal Chemistry Letters. 54: 128432. doi:10.1016/j.bmcl.2021.128432. PMID 34757217.
^ "Alalevonadifloxacin". AdisInsight. Springer Nature Switzerland AG.

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.